NovoCure (NVCR) Interest Expenses (2014 - 2022)

NovoCure has disclosed Interest Expenses across 9 years of filings, most recently posting $2.2 million for Q2 2022.

• Interest Expenses for Q2 2022 came in at $2.2 million, up 137.02% year-over-year; the trailing twelve-month figure through Mar 2023 was $2.2 million (down 67.26% YoY), and the FY2021 annual result was $7.7 million, down 37.05% from the prior year.
• Interest Expenses came in at $2.2 million for Q2 2022 at NovoCure, up from $1.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $4.9 million in Q1 2018 to a low of $940000.0 in Q2 2021.
• The 5-year median for Interest Expenses is $2.4 million (2018), against an average of $2.5 million.
• Across the five-year window, Interest Expenses tumbled 64.08% in 2021 and surged 137.02% in 2022, its largest moves.
• NovoCure's Interest Expenses stood at $2.2 million in 2018, then declined by 19.21% to $1.7 million in 2019, then surged by 87.22% to $3.3 million in 2020, then sank by 33.43% to $2.2 million in 2021, then gained by 2.44% to $2.2 million in 2022.
• The last three Interest Expenses figures came in at $2.2 million (Q2 2022), $1.7 million (Q1 2022), and $2.2 million (Q4 2021), per Business Quant data.